论文部分内容阅读
将聚乙二醇 (PEG)化学连接于治疗蛋白质能增加血浆半衰期、减少毒性、增强药物的稳定性和溶解性。PEG结合蛋白质通过减少免疫系统发现和攻击外源物的能力以增加其治疗效果。由活化的PEG单体与蛋白质偶联制备PEG蛋白结合物 ,这种偶联策略有多种选择。PEG化干扰素 α用于治疗慢性丙型肝炎病毒性感染已进行了大量临床研究工作 ,并获得肯定的疗效。已有 3种PEG蛋白结合物被FDA批准 ,临床应用于治疗严重的复合性免疫缺陷病和治疗各种白细胞增多症
Chemically linking polyethylene glycol (PEG) to therapeutic proteins increases plasma half-life, reduces toxicity, and enhances drug stability and solubility. PEG-binding proteins increase their therapeutic efficacy by reducing the immune system’s ability to detect and attack foreign substances. There are many options for this conjugation strategy by conjugating activated PEG monomers to proteins to make PEG conjugates. Pegylated interferon alpha has been used in a large number of clinical studies for the treatment of viral infections of chronic hepatitis C and has been affirmed that efficacy. Three PEG conjugates have been approved by the FDA for clinical use in the treatment of severe combined immunodeficiency disorders and the treatment of various leukocytosis